NASDAQ:MGTA - Magenta Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.97 -0.38 (-2.19 %) (As of 05/24/2019 04:00 PM ET)Previous Close$16.97Today's Range$16.79 - $17.8952-Week Range$5.31 - $21.00Volume57,096 shsAverage Volume179,948 shsMarket Capitalization$571.09 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Receive MGTA News and Ratings via Email Sign-up to receive the latest news and ratings for MGTA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGTA Previous Symbol CUSIPN/A CIKN/A Webhttp://www.magentatx.com/ Phone857-242-0170Debt Debt-to-Equity RatioN/A Current Ratio17.06 Quick Ratio17.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book4.26Profitability EPS (Most Recent Fiscal Year)($3.13) Net Income$-57,510,000.00 Net MarginsN/A Return on Equity-40.02% Return on Assets-37.17%Miscellaneous Employees59 Outstanding Shares33,653,000Market Cap$571.09 million Next Earnings Date8/8/2019 (Estimated) OptionableNot Optionable Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions What is Magenta Therapeutics' stock symbol? Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA." How were Magenta Therapeutics' earnings last quarter? Magenta Therapeutics Inc (NASDAQ:MGTA) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.11. View Magenta Therapeutics' Earnings History. When is Magenta Therapeutics' next earnings date? Magenta Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Magenta Therapeutics. What price target have analysts set for MGTA? 5 brokers have issued 12-month price objectives for Magenta Therapeutics' stock. Their forecasts range from $16.00 to $22.00. On average, they anticipate Magenta Therapeutics' share price to reach $18.6667 in the next year. This suggests a possible upside of 10.0% from the stock's current price. View Analyst Price Targets for Magenta Therapeutics. What is the consensus analysts' recommendation for Magenta Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Magenta Therapeutics. Has Magenta Therapeutics been receiving favorable news coverage? Media headlines about MGTA stock have trended positive on Saturday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Magenta Therapeutics earned a news impact score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. Are investors shorting Magenta Therapeutics? Magenta Therapeutics saw a drop in short interest in the month of April. As of April 15th, there was short interest totalling 1,744,802 shares, a drop of 42.1% from the March 29th total of 3,011,624 shares. Based on an average trading volume of 90,467 shares, the days-to-cover ratio is presently 19.3 days. Currently, 12.0% of the shares of the stock are sold short. View Magenta Therapeutics' Current Options Chain. Who are some of Magenta Therapeutics' key competitors? Some companies that are related to Magenta Therapeutics include Arrowhead Pharmaceuticals (ARWR), Ligand Pharmaceuticals (LGND), Emergent Biosolutions (EBS), Portola Pharmaceuticals (PTLA), Insmed (INSM), AnaptysBio (ANAB), Endocyte (ECYT), Akcea Therapeutics (AKCA), Allakos (ALLK), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Tricida (TCDA), Pacira Biosciences (PCRX), Supernus Pharmaceuticals (SUPN) and Ironwood Pharmaceuticals (IRWD). What other stocks do shareholders of Magenta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include T2 Biosystems (TTOO), Anavex Life Sciences (AVXL), Cidara Therapeutics (CDTX), Second Sight Medical Products (EYES), Ocular Therapeutix (OCUL), Progenics Pharmaceuticals (PGNX), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD), Agile Therapeutics (AGRX) and AVEO Pharmaceuticals (AVEO). Who are Magenta Therapeutics' key executives? Magenta Therapeutics' management team includes the folowing people: Mr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 48)Mr. Michael P. Cooke, Chief Scientific Officer (Age 57)Ms. Alison Lawton, Board Advisor (Age 58)Mr. Jason Ryan, Chief Operating & Financial Officer (Age 45)Ms. Manisha Pai, VP of Investor Relations & Communications When did Magenta Therapeutics IPO? (MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Magenta Therapeutics' major shareholders? Magenta Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (5.44%), BlackRock Inc. (3.30%), Opaleye Management Inc. (1.52%), Harvard Management Co. Inc. (0.97%), Principal Financial Group Inc. (0.69%) and Platinum Investment Management Ltd. (0.63%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, David Scadden and Jason Gardner. View Institutional Ownership Trends for Magenta Therapeutics. Which institutional investors are selling Magenta Therapeutics stock? MGTA stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Harvard Management Co. Inc., Principal Financial Group Inc., Platinum Investment Management Ltd., Morgan Stanley and Spark Investment Management LLC. View Insider Buying and Selling for Magenta Therapeutics. Which institutional investors are buying Magenta Therapeutics stock? MGTA stock was purchased by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, BlackRock Inc., Northern Trust Corp, BlueCrest Capital Management Ltd, Oppenheimer & Co. Inc., Charles Schwab Investment Management Inc., California State Teachers Retirement System and Rhumbline Advisers. Company insiders that have bought Magenta Therapeutics stock in the last two years include David Scadden and Jason Gardner. View Insider Buying and Selling for Magenta Therapeutics. How do I buy shares of Magenta Therapeutics? Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Magenta Therapeutics' stock price today? One share of MGTA stock can currently be purchased for approximately $16.97. How big of a company is Magenta Therapeutics? Magenta Therapeutics has a market capitalization of $571.09 million. The company earns $-57,510,000.00 in net income (profit) each year or ($3.13) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe. What is Magenta Therapeutics' official website? The official website for Magenta Therapeutics is http://www.magentatx.com/. How can I contact Magenta Therapeutics? Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected] MarketBeat Community Rating for Magenta Therapeutics (NASDAQ MGTA)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 74 (Vote Outperform)Underperform Votes: 100 (Vote Underperform)Total Votes: 174MarketBeat's community ratings are surveys of what our community members think about Magenta Therapeutics and other stocks. Vote "Outperform" if you believe MGTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Outstanding Shares Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.